A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 VEGF-反义寡核苷酸（VEGF-AS）每日固定剂量皮下注射治疗复发性或难治性恶性肿瘤患者的I期研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I study of VEGF-Antisense Oligonucleotide (VEGF-AS) given as a daily fixed dose subcutaneous injection in the treatment of patients with relapsed or refractory malignancies.